The discussions on listing the ultra-high-priced, one-shot treatment ‘Kymriah’ for health insurance benefits will begin.

According to industry sources, Novartis Korea’s first-in-class CAR-T (chimeric antigen receptor-T) treatment will be put as an agenda for deliberation in September at Health Insurance Review and Assessment Service’s Cancer Disease Review Committee (CDRC) meeting.

Kymriah, which was approved in March in Korea, used the ‘approval-benefit appraisal linkage system’ to promptly apply for insurance benefits. However, the agenda was not put up for deliberation by the Cancer Disease Review Committee last month, which gave rise to harsh criticism from the Korea Leukemia P